Evidence map›Paper›PMID 35223506›Full record

ReviewFrontiers in oncology2022

Molecular Pathways in Peritoneal Mesothelioma: A Minireview of New Insights.

Francesco Fortarezza, Federica Pezzuto, Andrea Marzullo, Domenica Cavone, Daniele Egidio Romano, Antonio d'Amati, Gabriella Serio, Luigi Vimercati

Abstract readReview
In one paragraph

Review in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Review
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Francesco FortarezzaDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, Pathology Unit, University of Padova, Padova, Italy.
Federica PezzutoDepartment of Cardiac, Thoracic, Vascular Sciences and Public Health, Pathology Unit, University of Padova, Padova, Italy.
Andrea MarzulloDepartment of Emergency and Organ Transplantation, Pathology Unit, University of Bari, Bari, Italy.
Domenica CavoneDepartment of Interdisciplinary Medicine, Occupational Health Unit, University of Bari, Bari, Italy.
Daniele Egidio RomanoDepartment of Emergency and Organ Transplantation, Pathology Unit, University of Bari, Bari, Italy.
Antonio d'AmatiDepartment of Emergency and Organ Transplantation, Pathology Unit, University of Bari, Bari, Italy.
Gabriella SerioDepartment of Emergency and Organ Transplantation, Pathology Unit, University of Bari, Bari, Italy.
Luigi VimercatiDepartment of Interdisciplinary Medicine, Occupational Health Unit, University of Bari, Bari, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Mesothelioma is a rare malignant neoplasm with poor survival. It mainly affects the pleura (90%) but can arise in all serous cavities: peritoneum (5-10%), pericardium and tunica vaginalis testis (<1%). The onset of pleural mesothelioma is strictly related to asbestos exposure with a long latency time. The causal link with asbestos has also been suggested for peritoneal mesothelioma, while the importance of exposure in the onset of pericardial and tunica vaginalis testis mesotheliomas is not well known. Mesothelioma remains an aggressive and fatal disease with a five-year mortality rate higher than 95%. However, new therapeutic approaches based on molecular-targeted and immunomodulatory therapies are being explored but have conflicting results. In this context, the identification of critical targets appears mandatory. Awareness of the molecular and physiological changes leading to the neoplastic degeneration of mesothelial cells and the identification of gene mutations, epigenetic alterations, gene expression profiles and altered pathways could be helpful for selecting targetable mechanisms and molecules. In this review, we aimed to report recent research in the last 20 years focusing on the molecular pathways and prognostic factors in peritoneal mesothelioma and their possible diagnostic and therapeutic implications.

Indexed as

asbestosmalignant mesotheliomamolecular pathwaysperitoneal mesotheliomaprognostic factors

Identifiers

PMID35223506
PMCPMC8866824

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.